2014 Q2 Form 10-Q Financial Statement
#000110465914039355 Filed on May 15, 2014
Income Statement
| Concept | 2014 Q2 | 2014 Q1 | 2013 Q4 |
|---|---|---|---|
| Revenue | $4.432M | $0.00 | $10.00K |
| YoY Change | 147633.33% | -100.0% | -47.37% |
| Cost Of Revenue | $5.009M | $0.00 | $0.00 |
| YoY Change | 500800.0% | -100.0% | |
| Gross Profit | -$577.0K | $0.00 | $10.00K |
| YoY Change | -28950.0% | -100.0% | -50.0% |
| Gross Profit Margin | -13.02% | 100.0% | |
| Selling, General & Admin | $3.581M | $1.374M | $1.620M |
| YoY Change | 129.55% | -15.86% | 0.0% |
| % of Gross Profit | 16200.0% | ||
| Research & Development | $4.364M | $3.271M | $3.320M |
| YoY Change | 18.72% | -40.94% | -44.76% |
| % of Gross Profit | 33200.0% | ||
| Depreciation & Amortization | $100.0K | $97.00K | $100.0K |
| YoY Change | -23.08% | -35.33% | -37.5% |
| % of Gross Profit | 1000.0% | ||
| Operating Expenses | $7.945M | $4.645M | $4.930M |
| YoY Change | 51.74% | -35.23% | -35.47% |
| Operating Profit | -$8.522M | -$4.645M | -$4.920M |
| YoY Change | 62.82% | -35.17% | -35.41% |
| Interest Expense | $2.000K | $2.000K | $2.010M |
| YoY Change | -33.33% | -33.33% | 107.22% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $3.884M | -$1.350M | |
| YoY Change | 1025.8% | -183.28% | |
| Pretax Income | -$4.640M | -$6.000M | -$2.920M |
| YoY Change | -5.11% | 8.3% | -56.09% |
| Income Tax | $0.00 | ||
| % Of Pretax Income | |||
| Net Earnings | -$4.638M | -$5.995M | -$2.920M |
| YoY Change | -5.13% | 8.13% | -56.09% |
| Net Earnings / Revenue | -104.65% | -29200.0% | |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$711.7K | -$1.022M | -$650.3K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 6.497M shares | 6.158M shares | 4.380M shares |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2014 Q2 | 2014 Q1 | 2013 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $7.300M | $8.800M | $8.100M |
| YoY Change | 62.22% | -4.35% | -40.44% |
| Cash & Equivalents | $7.300M | $8.800M | $8.059M |
| Short-Term Investments | |||
| Other Short-Term Assets | $610.0K | $400.0K | $409.0K |
| YoY Change | 158.47% | 33.33% | 16.19% |
| Inventory | $1.922M | $0.00 | |
| Prepaid Expenses | |||
| Receivables | $4.317M | $8.000K | |
| Other Receivables | $0.00 | $0.00 | |
| Total Short-Term Assets | $14.11M | $9.236M | $8.476M |
| YoY Change | 198.35% | -3.04% | -39.41% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $2.387M | $642.0K | $739.0K |
| YoY Change | 150.47% | -39.2% | -37.79% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | $3.337M | ||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | |||
| YoY Change | |||
| Total Long-Term Assets | $5.724M | $642.0K | $739.0K |
| YoY Change | 500.63% | -39.2% | -37.79% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $14.11M | $9.236M | $8.476M |
| Total Long-Term Assets | $5.724M | $642.0K | $739.0K |
| Total Assets | $19.84M | $9.878M | $9.215M |
| YoY Change | 249.04% | -6.65% | -39.29% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $2.909M | $2.500M | $2.355M |
| YoY Change | -11.85% | -16.67% | -17.16% |
| Accrued Expenses | $2.505M | $400.0K | $294.0K |
| YoY Change | 401.0% | -55.56% | -27.23% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $2.500M | $0.00 | $6.000K |
| YoY Change | |||
| Long-Term Debt Due | $2.000K | $6.000K | |
| YoY Change | -82.35% | ||
| Total Short-Term Liabilities | $17.05M | $6.109M | $5.321M |
| YoY Change | 343.81% | 42.87% | -5.97% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | -100.0% | |
| Other Long-Term Liabilities | |||
| YoY Change | |||
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | -100.0% | |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $17.05M | $6.109M | $5.321M |
| Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
| Total Liabilities | $17.10M | $6.100M | $5.321M |
| YoY Change | 345.08% | 42.59% | -6.07% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$293.8M | -$287.8M | |
| YoY Change | 4.13% | 4.52% | |
| Common Stock | $259.1M | $253.3M | |
| YoY Change | 5.53% | 4.13% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $2.785M | $3.769M | $3.894M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $19.84M | $9.878M | $9.215M |
| YoY Change | 249.04% | -6.81% | -39.29% |
Cashflow Statement
| Concept | 2014 Q2 | 2014 Q1 | 2013 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$4.638M | -$5.995M | -$2.920M |
| YoY Change | -5.13% | 8.13% | -56.09% |
| Depreciation, Depletion And Amortization | $100.0K | $97.00K | $100.0K |
| YoY Change | -23.08% | -35.33% | -37.5% |
| Cash From Operating Activities | -$6.070M | -$4.670M | -$4.340M |
| YoY Change | 29.15% | -30.92% | -40.87% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$10.00K | $0.00 | $0.00 |
| YoY Change | -50.0% | -100.0% | -100.0% |
| Acquisitions | $0.00 | ||
| YoY Change | |||
| Other Investing Activities | $1.050M | $0.00 | $0.00 |
| YoY Change | |||
| Cash From Investing Activities | $1.040M | $0.00 | $0.00 |
| YoY Change | -5300.0% | -100.0% | -100.0% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $5.286M | ||
| YoY Change | |||
| Debt Paid & Issued, Net | $4.000K | ||
| YoY Change | -63.64% | ||
| Cash From Financing Activities | 3.460M | 5.450M | 1.580M |
| YoY Change | -34700.0% | 129.96% | -15900.0% |
| NET CHANGE | |||
| Cash From Operating Activities | -6.070M | -4.670M | -4.340M |
| Cash From Investing Activities | 1.040M | 0.000 | 0.000 |
| Cash From Financing Activities | 3.460M | 5.450M | 1.580M |
| Net Change In Cash | -1.570M | 780.0K | -2.760M |
| YoY Change | -66.81% | -117.69% | -62.95% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$6.070M | -$4.670M | -$4.340M |
| Capital Expenditures | -$10.00K | $0.00 | $0.00 |
| Free Cash Flow | -$6.060M | -$4.670M | -$4.340M |
| YoY Change | 29.49% | -31.1% | -40.06% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2014Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
15000000 | shares |
| CY2014Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
6245000 | shares |
| CY2014Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
6245000 | shares |
| CY2013Q4 | us-gaap |
Common Stock No Par Value
CommonStockNoParValue
|
||
| CY2013Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
15000000 | shares |
| CY2013Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5538000 | USD |
| CY2013Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
1633000 | USD |
| CY2014Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
1374000 | USD |
| us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
99847000 | USD | |
| CY2013Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
7173000 | USD |
| CY2014Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
4645000 | USD |
| us-gaap |
Costs And Expenses
CostsAndExpenses
|
338003000 | USD | |
| CY2013Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-7165000 | USD |
| CY2014Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4645000 | USD |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-324080000 | USD | |
| CY2013Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-1619000 | USD |
| CY2014Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
1352000 | USD |
| us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-20522000 | USD | |
| us-gaap |
Other Nonoperating Income
OtherNonoperatingIncome
|
1249000 | USD | |
| CY2013Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
5000 | USD |
| CY2014Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
4000 | USD |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
10842000 | USD | |
| CY2013Q1 | us-gaap |
Interest Expense
InterestExpense
|
3000 | USD |
| CY2014Q1 | us-gaap |
Interest Expense
InterestExpense
|
2000 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
504000 | USD | |
| CY2013Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1621000 | USD |
| CY2014Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1350000 | USD |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
32109000 | USD | |
| CY2013Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5544000 | USD |
| CY2014Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5995000 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-291971000 | USD | |
| CY2014Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2014Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2014Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
6497127 | shares |
| CY2014Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2014 | |
| CY2014Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2014Q1 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">2.   Basis of Presentation</font></b></p> <p style="TEXT-ALIGN: justify; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 13.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The condensed consolidated financial statements included herein have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC).  Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP) have been omitted pursuant to such rules and regulations. The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated.  The results of operations for the three months ended March 31, 2014, are not necessarily indicative of the results to be expected for the full year or for any other period.  The December 31, 2013 condensed consolidated balance sheet data was derived from audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP.</font></p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 13.5pt; MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 13.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the period ended December 31, 2013, as filed with the SEC.</font></p> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p> <p style="TEXT-ALIGN: justify; TEXT-INDENT: 13.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The consolidated financial statements include the accounts of Aastrom and its wholly-owned subsidiaries, Aastrom Biosciences GmbH, located in Berlin, Germany and Marrow Donation, LLC, located in San Diego, California (collectively, the Company).  All inter-company transactions and accounts have been eliminated in consolidation.  The subsidiaries are not a significant component of the consolidated financial statements as each has limited operations historically and Aastrom Biosciences GmbH has ceased operations.</font></p> </div> | |
| CY2014Q1 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | segment |
| CY2014Q1 | us-gaap |
Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
|
145000 | USD |
| CY2014Q1 | astm |
Maximum Period Before Cash And Cash Equivalents Are Fully Depleted
MaximumPeriodBeforeCashAndCashEquivalentsAreFullyDepleted
|
P1Y | |
| CY2014Q1 | astm |
Minimum Period Of Uncertainty Regarding Entitys Ability To Maintain Liquidity Sufficient To Operate Business Effectively
MinimumPeriodOfUncertaintyRegardingEntitysAbilityToMaintainLiquiditySufficientToOperateBusinessEffectively
|
P12M | |
| us-gaap |
Stock And Warrants Issued During Period Value Preferred Stock And Warrants
StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants
|
10527000 | USD | |
| CY2013Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
417000 | USD |
| CY2014Q1 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
400000 | USD |
| CY2013Q4 | us-gaap |
Assets Current
AssetsCurrent
|
8476000 | USD |
| CY2014Q1 | us-gaap |
Assets Current
AssetsCurrent
|
9236000 | USD |
| CY2013Q1 | us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
8000 | USD |
| us-gaap |
Sales Revenue Goods Net
SalesRevenueGoodsNet
|
1917000 | USD | |
| astm |
Research And Development Agreements
ResearchAndDevelopmentAgreements
|
2105000 | USD | |
| CY2013Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-6807000 | USD |
| CY2014Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-7413000 | USD |
| CY2013Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
2243000 | shares |
| CY2014Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
5868000 | shares |
| CY2013Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-3.00 | |
| CY2014Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.26 | |
| CY2013Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
739000 | USD |
| CY2013Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1528000 | shares |
| CY2014Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2510000 | shares |
| CY2014Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
642000 | USD |
| CY2013Q4 | us-gaap |
Assets
Assets
|
9215000 | USD |
| CY2014Q1 | us-gaap |
Assets
Assets
|
9878000 | USD |
| CY2013Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
2676000 | USD |
| CY2014Q1 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
2475000 | USD |
| CY2013Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
620000 | USD |
| CY2014Q1 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
406000 | USD |
| CY2013Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
6000 | USD |
| CY2014Q1 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
2000 | USD |
| CY2013Q4 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
2019000 | USD |
| CY2014Q1 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
3226000 | USD |
| CY2013Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
5321000 | USD |
| CY2014Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
6109000 | USD |
| CY2013Q4 | us-gaap |
Cash
Cash
|
8059000 | USD |
| CY2014Q1 | us-gaap |
Cash
Cash
|
8836000 | USD |
| CY2013Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
253270000 | USD |
| CY2014Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
259140000 | USD |
| CY2013Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-287765000 | USD |
| CY2014Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-293760000 | USD |
| CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3894000 | USD |
| CY2014Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3769000 | USD |
| CY2013Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
9215000 | USD |
| CY2014Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
9878000 | USD |
| us-gaap |
Revenue From Grants
RevenueFromGrants
|
9901000 | USD | |
| CY2013Q1 | us-gaap |
Sales Revenue Net
SalesRevenueNet
|
8000 | USD |
| us-gaap |
Sales Revenue Net
SalesRevenueNet
|
13923000 | USD | |
| CY2013Q1 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
2000 | USD |
| CY2013Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
150000 | USD |
| CY2013Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
-43000 | USD |
| CY2014Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
97000 | USD |
| CY2014Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
270000 | USD |
| us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
8733000 | USD | |
| us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-110000 | USD | |
| us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
-1704000 | USD | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
18691000 | USD | |
| us-gaap |
Inventory Write Down
InventoryWriteDown
|
2240000 | USD | |
| us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
3300000 | USD | |
| us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
204000 | USD | |
| CY2013Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-52000 | USD |
| CY2013Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-232000 | USD |
| CY2013Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
475000 | USD |
| CY2014Q1 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
-17000 | USD |
| CY2014Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-201000 | USD |
| CY2014Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-214000 | USD |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
2335000 | USD | |
| us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
629000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
2243000 | USD | |
| us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
406000 | USD | |
| CY2013Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-6761000 | USD |
| CY2014Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-4674000 | USD |
| us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-281234000 | USD | |
| CY2013Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
18000 | USD |
| CY2013Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-18000 | USD |
| astm |
Organizational Costs Activity
OrganizationalCostsActivity
|
73000 | USD | |
| us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
217041000 | USD | |
| us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
218745000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
7530000 | USD | |
| us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
400000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-5499000 | USD | |
| CY2013Q1 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
2378000 | USD |
| CY2013Q1 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
11000 | USD |
| CY2013Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
2367000 | USD |
| CY2014Q1 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
5455000 | USD |
| CY2014Q1 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
4000 | USD |
| CY2014Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
5451000 | USD |
| us-gaap |
Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
|
89267000 | USD | |
| us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
204947000 | USD | |
| us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
3500000 | USD | |
| us-gaap |
Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
|
751000 | USD | |
| us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
2878000 | USD | |
| us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-18000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
295569000 | USD | |
| CY2013Q1 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
-4412000 | USD |
| CY2014Q1 | us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
777000 | USD |
| us-gaap |
Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
|
8836000 | USD | |
| CY2013Q1 | us-gaap |
Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
|
1263000 | USD |
| us-gaap |
Preferred Stock Accretion Of Redemption Discount
PreferredStockAccretionOfRedemptionDiscount
|
6224000 | USD | |
| CY2014Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
5286000 | USD |
| CY2012Q4 | us-gaap |
Cash
Cash
|
13638000 | USD |
| CY2013Q1 | us-gaap |
Cash
Cash
|
9226000 | USD |
